SKYE
Income statement / Annual
Last year (2025), Skye Bioscience Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Skye Bioscience Inc's net income was -$55.92 M.
See Skye Bioscience Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$723.35 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.87 K
|
$1.46 K
|
$1.54 K
|
$8.04 K
|
$14.92 K
|
| Gross Profit |
-$723.35 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.87 K
|
-$1.46 K
|
-$1.54 K
|
-$8.04 K
|
-$14.92 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$42.36 M
|
$18.70 M
|
$5.82 M
|
$6.01 M
|
$2.93 M
|
$1.94 M
|
$2.24 M
|
$329.97 K
|
$311.30 K
|
$939.04 K
|
| General & Administrative Expenses |
$15.80 M
|
$17.73 M
|
$7.85 M
|
$6.09 M
|
$4.92 M
|
$4.35 M
|
$4.40 M
|
$4.36 M
|
$3.55 M
|
$3.53 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.80 M
|
$17.73 M
|
$7.85 M
|
$6.09 M
|
$4.92 M
|
$4.35 M
|
$4.40 M
|
$4.36 M
|
$3.55 M
|
$3.53 M
|
| Other Expenses |
-$723.35 K
|
-$6.23 M
|
$21.06 M
|
$6.21 M
|
$0.00
|
$0.00
|
$2.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$57.44 M
|
$30.19 M
|
$34.74 M
|
$18.31 M
|
$7.85 M
|
$6.29 M
|
$6.63 M
|
$4.69 M
|
$3.86 M
|
$4.47 M
|
| Cost And Expenses |
$58.16 M
|
$30.19 M
|
$34.74 M
|
$18.31 M
|
$7.85 M
|
$6.29 M
|
$6.63 M
|
$4.69 M
|
$3.86 M
|
$4.47 M
|
| Interest Income |
$1.88 M
|
$3.26 M
|
$99.97 K
|
$19.01 K
|
$3.00
|
$29.00
|
$26.00
|
$84.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$967.60 K
|
$906.27 K
|
$663.77 K
|
$767.51 K
|
$706.39 K
|
$1.00 M
|
$94.76 K
|
$667.00
|
$0.00
|
| Depreciation & Amortization |
$723.35 K
|
$298.64 K
|
$124.25 K
|
$115.00 K
|
$34.13 K
|
$1.87 K
|
$1.46 K
|
$1.54 K
|
$8.04 K
|
$14.92 K
|
| EBITDA |
-$55.20 M |
-$25.29 M |
-$36.62 M |
-$18.70 M |
-$7.72 M |
-$5.85 M |
$2.04 M |
-$4.69 M |
-$3.08 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.24 M
|
$3.64 M
|
-$2.91 M
|
-$1.16 M
|
-$672.37 K
|
-$270.00 K
|
$7.69 M
|
-$14.50 M
|
$766.53 K
|
$1.29 M
|
| Income Before Tax |
-$55.92 M
|
-$26.56 M
|
-$37.64 M
|
-$19.47 M
|
-$8.52 M
|
-$6.56 M
|
$1.05 M
|
-$19.19 M
|
-$3.09 M
|
-$3.18 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$5.40 K
|
$10.07 K
|
$3.60 K
|
$6.74 K
|
$2.10 K
|
$1.60 K
|
$1.60 K
|
$1.64 K
|
$1.60 K
|
$1.60 K
|
| Net Income |
-$55.92 M
|
-$26.57 M
|
-$37.64 M
|
-$19.48 M
|
-$8.52 M
|
-$6.56 M
|
$1.05 M
|
-$19.19 M
|
-$3.09 M
|
-$3.18 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-11.28 |
-5.84 |
-42.96 |
-70.16 |
-40 |
-56.88 |
15.84 |
-292.08 |
-204.96 |
-335.44 |
| EPS Diluted |
-11.28 |
-5.84 |
-42.96 |
-70.16 |
-40 |
-59.68 |
15.84 |
-292.08 |
-204.96 |
-319.2 |
| Weighted Average Shares Out |
$4.96 M
|
$4.56 M
|
$875.75 K
|
$277.64 K
|
$203.30 K
|
$115.37 K
|
$66.50 K
|
$65.72 K
|
$15.10 K
|
$9.47 K
|
| Weighted Average Shares Out Diluted |
$4.96 M
|
$4.56 M
|
$875.75 K
|
$277.64 K
|
$203.30 K
|
$115.71 K
|
$66.50 K
|
$65.72 K
|
$15.10 K
|
$9.96 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
